Neurology

GlaxoSmithKline taps Baltimore’s Insilico for AI-based drug discovery GlaxoSmithKline and Insilico Medicine are partnering to explore how the latter’s artificial intelligence technology can aid in the drug discovery process. The duo kept mum on the details but said the agreement comes after Baltimore-based Insilico completed a series of pilot challenges. First, Glaxo will evaluate Insilico’s technology in the identification of novel biological targets and pathways of interest. Based at Johns Hopkins University’s Emerging Technology Centers, Insilico uses genomics, big data analysis and deep learning for in silico drug discovery, or drug discovery through computer model...